Key Highlights
- Biogen has entered into an agreement to purchase Apellis Pharmaceuticals for roughly $5.6 billion in an all-cash transaction.
- The deal values Apellis at $41 per share, representing approximately a 140% premium over its previous trading price.
- Additional contingent value rights of up to $4 per share are available based on Syfovre sales performance metrics.
- The acquisition brings Empaveli and Syfovre into Biogen’s portfolio, products that delivered $689 million in combined sales in 2025.
- Transaction completion is anticipated during Q2 2026.
Shares of Apellis Pharmaceuticals (APLS) skyrocketed more than 136% during pre-market hours on Tuesday, March 31, following Biogen’s (BIIB) announcement of its intention to acquire the specialty pharmaceutical company for approximately $5.6 billion. In contrast, Biogen’s stock declined nearly 7% following the disclosure.
Apellis Pharmaceuticals, Inc., APLS
The $41-per-share all-cash proposal from Biogen delivers a substantial premium of roughly 140% compared to APLS’s closing price from the prior trading session.
This transaction aligns with Biogen’s broader strategic objective to diversify away from declining multiple sclerosis franchise revenues by expanding its presence in immunology and rare disease therapeutics.
The acquisition provides Biogen with immediate access to two commercially approved therapeutics. Empaveli has received regulatory approval for treating two uncommon kidney conditions and a rare hematological disorder. Syfovre addresses geographic atrophy in its advanced stages, a significant contributor to vision loss globally.
The combined product portfolio generated roughly $689 million in revenue during 2025. Both companies anticipate this revenue stream will expand at a mid-to-high teens percentage rate annually through 2028 at minimum.
Additional Milestone-Based Compensation Structure
In addition to the $41 baseline per-share payment, Apellis shareholders stand to gain two separate contingent payments valued at $2 each—potentially adding $4 per share in total—tied to achieving predetermined worldwide sales benchmarks for Syfovre.
This structure establishes a maximum potential value of $45 per share should all performance targets be satisfied.
Christopher Viehbacher, Biogen’s CEO, characterized the transaction as aligned with the company’s strategic evolution. “The addition of Apellis expands our growth portfolio in immunology and rare disease with two approved, best-in-class medicines that complement our existing portfolio,” he stated.
Subject to customary regulatory clearances and shareholder consent, the transaction is projected to finalize during the second quarter of 2026.
Investor Response to Biogen’s Move
While shareholders of APLS benefited substantially, Biogen’s equity experienced downward pressure immediately after the announcement, dropping approximately 7% in pre-market activity.
Such negative market reactions are typical for acquiring companies offering significant premiums. Multi-billion dollar all-cash acquisitions frequently create near-term headwinds for the buyer’s stock performance.
According to TipRanks, BIIB maintains a Moderate Buy consensus rating derived from 11 Buy recommendations, 15 Hold ratings, and 1 Sell rating. Analysts have established a consensus price target of $206.70, suggesting approximately 10% appreciation potential from current levels, with a high-end target of $250.
This deal represents Biogen’s continued efforts to pivot from its traditional multiple sclerosis franchise toward faster-growing rare disease treatment categories.
Prior to the takeover announcement, Apellis stock was trading at approximately $17 per share, based on the differential between that level and the offered $41 purchase price.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
